Hemoperfusion in Critical Patients With Septic Multiorgan Dysfunction Syndrome.

Launched by HOSPITAL CLINIC OF BARCELONA · Sep 6, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called hemoperfusion for patients who are critically ill with a serious condition known as septic multiorgan dysfunction syndrome. This condition happens when an infection in the body leads to multiple organs not working properly. The trial aims to find out how safe and effective hemoperfusion is in helping these patients, especially those who have not responded well to standard treatments for sepsis.

To be eligible for this study, patients must be between the ages of 65 and 80 and diagnosed with sepsis, particularly from an abdominal infection. They should also be experiencing dysfunction in two or more organs and need support to maintain proper blood flow. However, certain patients will not qualify, including those under 18 or over 80, pregnant women, and those who are very ill with a short life expectancy. If someone joins the trial, they can expect to receive close monitoring and care while receiving this treatment. Participation in this study may help researchers understand how to better manage severe infections in critically ill patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Patients with a sepsis diagnosis, according to the diagnostic criteria of the International Sepsis-3 Consensus Conference, and without response to the treatment of septic shock who meet the following conditions:
• • Sepsis of abdominal origin with controlled infectious focus.
• • Noradrenaline dose\> 0.5 µg / kg / min to maintain adequate organ perfusion after optimization of fluid therapy.
• • Dysfunction of two or more organs with SOFA ≥ 9 (5).
• • Blood lactate ≥ 2 mmol / L.
• • Procalcitonin (PCT)\> 10 ng / mL.
• • CRP\> 100 mg / L.
• • IL-6\> 2000 pg / ml.
• Exclusion Criteria:
• • Age under 18 years or over 80 years.
• • Pregnancy or breastfeeding.
• • Terminally ill patients or with a life expectancy of less than 48 hours.
• • Thrombocytopenia \<60,000 / mm3.
• • Pancytopenia.
• • Severe coagulopathy with high risk of bleeding.
• • Inclusion in another research protocol.
• • In case of re-entry during the study period, only the first admission will be included.
• • Use of another haemoperfusion device.